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585Abstracts
the IPSS score was respectively 14.3 (6.6) and 11.9 (5.7)
upon patient inclusion and after 6 months. The noted 
difference is statistically signiﬁcant (p < 0.0001). CON-
CLUSION: Patients suffering from a recently diagnosed
BPH and treated with Serenoa Repens thus showed a sta-
tistically signiﬁcant improvement as demonstrated by the
IPSS score.
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OBJECTIVES: The objective of this study was to use con-
joint analysis (CA) to measure patients’ valuations of the
characteristics of drugs used to treat overactive bladder
(OAB) in monetary terms. METHODS: A CA survey
using a discrete choice method was administered in inter-
views with OAB patients in three clinics in the UK
between July 1999 and April 2000. The survey consisted
of a series of pairs of hypothetical OAB drug proﬁles
described in terms of treatment attributes with varying
levels. For each pair the patients were asked to select the
drug proﬁle they preferred. The drug proﬁles included
efﬁcacy attributes (e.g. reduction in urinary incontinence)
and side-effect attributes (e.g. incidence of dry mouth). A
cost attribute was included to allow the calculation of
patients’ valuations of the different attributes in mone-
tary terms. RESULTS: One thousand ﬁve hundred 
twenty discrete choice comparisons of hypothetical OAB
drug treatments were obtained from 95 patients. Based
on these responses, a logit model was estimated that
attempted to explain the reasons why the respondents
made the choices they did. From this model, it is possi-
ble to derive estimates of the implied willingness-to-pay
(WTP) of patients for improvements in OAB drug efﬁcacy
rates and for the incidence of OAB drug-related side
effects. Improvements in efﬁcacy attributes have positive
WTP estimates (from £2.20 to £11.22 per day) and the
WTP estimates are negative for the incidence of side-effect
attributes (from -£2.79 to -£9.83 per day). CONCLU-
SIONS: This study demonstrates the capability of the CA
technique to measure valuations of varying drug proﬁles
in monetary terms. The results of this study could be used
to estimate the WTP of patients for different OAB drug
treatments.
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OBJECTIVES: Overactive Bladder (OAB) patients with
symptoms of frequency, urgency, and urge incontinence
treated with tolterodine showed signiﬁcant improvement
over placebo on 6 (4mg ER) or seven (2mg IR) of 10
King’s Health Questionnaire (KHQ) domains in a 12-
week randomized, double-blind trial (Phase A). Patients
were permitted to continue in a 12-month open-label
study (Phase B) to assess long-term effects of toltero-
dine ER. Regional differences in treatment effects on
health-related quality of life (HRQoL) were assessed.
METHODS: The KHQ was administered at baseline, end
of Phase A, and after 3 and 12 months in Phase B. An
intent-to-treat population for whom KHQ translations
were available (n = 858) was used in ANCOVA models
with baseline score, age, and gender as covariates. Region
and placebo effects were measured using a model with
treatment, region, and treatment by region as factors.
Long-term effects of tolterodine were assessed using a
split plot, repeated measures model where visits and treat-
ment were factors. RESULTS: Change from baseline to
end of Phase B analysis showed no signiﬁcant differences
in KHQ scores between patients in North America (US =
439, Canada = 67) and the rest of the world (Europe plus
Australia and New Zealand [EU+, n = 332]). Only the
Personal Relationships domain showed evidence of a
region interaction effect. Change from rollover analysis
of a subgroup of U.S. patients (n = 305) showed that
treatment effects persisted (8 domains) or improved (2
domains) after 12 months of additional treatment. These
results are generally consistent with the pooled analysis.
CONCLUSIONS: Treatment with tolterodine improves
HRQoL and improvements observed after initial treat-
ment persist in the longer term. In general, physical 
and symptom domains improved quickly and changes in
social and psychological domains became evident after
longer treatment. There does not appear to be a differ-
ence in these effects by region.
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